| 141/297 | US=47 / Câncer Sarli V, Giannis A. Kinesin motor inhibitors as effective anticancer drugs. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 207-26. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES KINESIN; DROGAS ANTICANCER; KINESINAS; ANTIMITOTICOS; EG5 HUMANA |
| 142/297 | US=47 / Câncer Shakalya K, Mahadevan D. Antiproliferation inhibitors targeting aurora kinases. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 243-69. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES ANTI-PROLIFERACAO; AURORA QUINASE; MITOSE; CICLO CELULAR; PROTO-ONCOGENES; INIBIDORES DA PROTEINA-QUINASE; ANEUPLOIDIA; CITOCINESE |
| 143/297 | US=47 / Câncer Dai W, Yang Y, Jiang N. Plks as novel targets for cancer drug design. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 271-90. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. PLKS; MEDICAMENTO ANTICANCER; POLO-LIKE QUINASES; PLK1; MITOSE; INIBIDORES; DROGAS ANTI-CANCER; FOSFORILACAO |
| 144/297 | US=47 / Câncer Gabrielli B, Stevens F, Beamish H. Do histone deacetylase inhibitors target cell cycle checkpoints that monitor heterochromatin structure?. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 291-309. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES DAS HISTONAS DESACETILASES; CONTROLE DO CICLO CELULAR; HETEROCROMATINA; LETALIDADE SINTETICA; PASSAGEIROS CROMOSSOMICOS |
| 145/297 | US=49-D / Câncer Cao Y. Molecular mechanisms and therapeutic development of angiogeneseis inhibitors. In: Woude GFV, Klein G. Advances in cancer research. v.100. Amsterdam: Elsevier, 2008. p. 113-31. ISBN 978-0-12-374358-9. INIBIDORES DA ANGIOGENESE; MECANISMOS MOLECULARES; DESENVOLVIMENTO TERAPEUTICO; FATORES ANGIOGENICOS TUMORAIS; VASOS SANGUINEOS; ALVOS TERAPEUTICOS; RESISTENCIA A DROGAS; MECANISMOS DE INIBIDORES; TERAPIA ANTIANGIOGENICA; QUIMIOTERAPIA; BIOMARCADORES |
| 146/297 | US=56 / Biol/Mol Mor G, Montagna MK, Alvero AB. Modulation of apoptosis to reverse chemoresistance. In: Mor G, Alvero AB. Apoptosis and cancer: methods and protocols. New Jersey: Humana Press, 2008. p. 1-12. (Methods in Molecular Biology) ISBN 978-1-58829-457-9. APOPTOSE; QUIMIORRESISTENCIA; CANCER DE OVARIO; PHENOXODIOL; CASPASE; INIBIDORES DA APOPTOSE; REGULACAO DO XIAP |
| 147/297 | US=57 / Biol/Mol Weinberg RA. Tratamento racional do câncer. In: ___. A biologia do câncer. Porto Alegre: Artmed, 2008. p. 725-96. ISBN 978-85-363-1348-1. TRATAMENTO RACIONAL DO CANCER; DROGAS ANTICANCER; INIBIDORES DE PROTEASSOMAS |
| 148/297 | US=64 / Câncer Dai Y, Grant S. CDK inhibitors in multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 331-63. (Comtemporary Hematology) ISBN 978-1-934115-82-4. INIBIDORES DE CDK NO MIELOMA MULTIPLO; PROGRESSAO DO CICLO CELULAR; QUINASES DEPENDENTES DE CICLINA |
| 149/297 | US=64 / Câncer Chauhan D, Singh A, Anderson K. Proteasome inhibitors as therapy in multiple myeloma. In: Lonial S. Mylenoma therapy: pursuing the plasma cell. 5th ed. New Jersey: Humana Press, 2008. p. 421-32. (Comtemporary Hematology) ISBN 978-1-934115-82-4. TERAPIA EM MIELOMA MULTIPLO. INIBIDORES DE PROTEASSOMA; HOMEOSTASE CELULAR NORMAL; AGENTES ANTICANCERIGENOS. INIBIDORES DE PROTEASSOMA |
| 150/297 | US=65 / Biol/Mol Jost M, Vosseler S, Blacher S, Fusenig NE, Mueller MM, Noël A. The surface transplantation model to study the tumor-host interface. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 327-42. ISBN 978-0-387-69056-8. MODELO DE TRANSPLANTE DE SUPERFICIE; TUMOR-HOSPEDEIRO; CARCINOMA DE CELULAS ESCAMOSAS DA PELE; INVASAO DE CELULA TUMORAL; INIBIDORES DE PROTEASES; COMPARTIMENTO DE TUMOR; CAMUNDONGOS DEFICIENTES; MMP; TUMOR ESTROMAL |
| 151/297 | US=65 / Biol/Mol Pennington CJ, Pilgrim S, Span PN, Sweep FC, Edwards DR. Novel degradome markers in breast cancer. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 627-43. ISBN 978-0-387-69056-8. CANCER DE MAMA; MARCADORES DEGRADOME; ASSINATURAS DE EXPRESSAO; PERFIL DE EXPRESSAO DEGRADOME; METALOPROTEINASE POTENCIAL; MARCADORES INIBIDORES |
| 152/297 | US=65 / Biol/Mol Yiotakis A, Dive V. Third-Generation MMP inhibitors: recent advances in the development of highly selective inhibitors. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 811-25. ISBN 978-0-387-69056-8. INIBIDORES DE MMP; GRUPOS DE LIGACAO DE ZINCO; FOSFINICOS; TRANSICAO ANALOGOS |
| 153/297 | US=67 / Biol/Mol Knights CD, Pestell RG. The cell cycle: therapeutic targeting of cell regulatory components and effector pathways in cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 3-32. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CICLO CELULAR; SEGMENTACAO TERAPEUTICA; COMPONENTES CELULARES; VIAS REGULADORAS; CANCER; CICLINA DEPENDENTE DE QUINASE; INIBIDORES CDK; TERAPIA; ACETILACAO; P53; CICLINA D1; EGFR; HDAC; STI-571; FLAVOPIRIDOL; INIBIDOR CDK2 |
| 154/297 | US=67 / Biol/Mol Easton JB, Houghton PJ. mTOR: properties and therapeutics. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 33-53. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. MTOR; PROPRIEDADES; TERAPEUTICA; INIBIDORES; RAPAMICINA; CANCER; ENSAIOS CLINICOS |
| 155/297 | US=67 / Biol/Mol Sparano JA. Ras/Raf/MEK inhibitors. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 55-73. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. |
| 156/297 | US=67 / Biol/Mol Heath EI, Carducci MA. Targeted therapies for prostate cancer. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 263-90. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER DE PROSTATA; TERAPIA-ALVO; INIBIDORES DA VIA DE SINALIZACAO; INIBIDORES DA ANGIOGENESE; IMUNOTERAPIA; AGENTES ANTI-TUBULINA; AGENTES ANTI-MITOTICOS; AGENTES DE SEGMENTACAO ANTI-VASCULARES |
| 157/297 | US=69 / Câncer Estey E. Targeted therapy in acute myelogenous leukemia. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 21-42. ISBN 978-1-60327-423-4. TERAPIA DE CANCER DIRECIONADA; TERAPIA-ALVO NA LEUCEMIA MIELOIDE AGUDA; LEUCEMIA MIELOIDE AGUDA; ATRA E ARSENICO TRIOXIDO OZOGAMICINA; FLT-3 INIBIDORES; INIBIDORES DA FARNESIL TRANSFERASE; EPIGENETICA AGENTES DE ACAO |
| 158/297 | US=7 / Tórax Tarantino AB, Sobreiro MC, Salluh J. Antimicrobianos nas infecções pulmonares. In: Tarantino AB. Doenças pulmonares. 6ª ed. Rio de Janeiro: Guanabara Koogan, 2008. p. 246-56. ISBN 85-2771333-7. INFECCAO PULMONAR; PENICILINA; CEFALOSPORINA; INIBIDORES DE BETA-LACTAMASE; ANTIBIOTICOS BETA-LACTAMICOS; CARBAPENEMA; MONOBACTAMICOS; GLICOPEPTIDEOS; AMINOGLICOSIDEOS; MACROLIDEOS; CLINDAMICINA; CLORANFENICOL; TIANFENICOL; KETOLIDEO; TETRACICLINA; SULFAMETOXAZOL; TRIMETOPRIM; QUINOLONA; ESTREPTOGRAMINA; OXAZOLIDINONA; METRONIDAZOL; ANTIFUNGICOS |
| 159/297 | US=58 / Câncer Eastman A. The importance of p53 signaling in the response of cells to checkpoint inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 189-98. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DANOS NO DNA; PARADA DO CICLO CELULAR; P53; P21; CICLINA B; CHK1 INIBIDORES; UCN-01; INIBIDORES DA TOPOISOMERASE II; ANALOGOS DE NUCLEOSIDOS |
| 160/297 | US=58 / Câncer Zhang H, Xiao Z, Sowin T. ChK1 and ChK2 as checkpoint targets. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 245-59. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CHK1; CHK2; INIBIDORES; PARADA DO CICLO CELULAR; REVOGACAO DA RESPOSTA CHECKPOINT; CHEMOPROTECTION; BIOMARCADORES PREDITIVOS |